We appreciate the interest and comments by Dr Linnankivi regarding our article entitled ''Allo-SCT in a patient with CRMCC with aplastic anemia using a reduced intensity conditioning regimen''. 1 The relationship between Revesz syndrome and cerebroretinal microangiopathy with calcifications and cysts (CRMCC) was not clear until the CTC1 (encoding conserved telomere maintenance component 1) mutation was identified. 2, 3 The definition of CRMCC originally encompassed Coats plus syndrome, Labrune syndrome and leukoencephalopathy, the brain calcifications and cysts of which are associated with characteristic central nervous system abnormalities, such as extensive intracranial calcification and leukoencephalopathy. 4 Coats plus syndrome is also characterized by the presence of bilateral exudative retinopathy. 4 In addition, some Coats plus patients show evidence of nail dystrophy, sparse hair and anemia, which are similar to the symptoms of dyskeratosis congenita (DKC). 5 On the other hand, Revesz syndrome was originally described in a male infant with bilateral exudative retinopathy, intracranial calcifications, cysts in the brain, leukoencephalopathy and aplastic anemia. 6 These findings suggested that Revesz syndrome might be a severe variant of Coats plus syndrome. Therefore, we experienced difficulty in clinically distinguishing Revesz syndrome from CRMCC/Coats plus syndrome based on the severity of the hematological complications. Recently, a TINF2 mutation was identified in patients with DKC and Revesz syndrome, suggesting that Revesz syndrome is, in fact, a variant of DKC. 7, 8 Subsequently, Anderson et al. 2 and Polvi et al. 3 identified mutations in the CTC1 gene that were responsible for Coats plus syndrome in some patients. Therefore, we diagnosed our patient with Coats plus syndrome based on these genetic abnormalities, leading to further understanding of the phenotypic details/differences caused by these genetic alterations. However, we now agree that our patient has Revesz syndrome harboring the TINF2 mutation, 7, 8 which is distinct from CRMCC/Coats plus syndrome harboring mutations in CTC1. 2, 3 Further genetic analyses are needed to examine whether the CTC1 mutation causes severe aplastic anemia, especially in DKC patients with unidentified genetic alterations, because TINF2 mutations have been identified in DKC patients without any symptoms of Revesz syndrome. 8 Therefore, it is mandatory that allogeneic hematopoietic SCT with a reduced intensity conditioning regimen should be considered for all patients with severe aplastic anemia harboring genetic alterations that cause telomere dysfunction. 9 
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